Literature DB >> 1856735

A short plasma exchange protocol is effective in severe myasthenia gravis.

C Antozzi1, M Gemma, B Regi, E Berta, P Confalonieri, D Peluchetti, R Mantegazza, F Baggi, M Marconi, F Fiacchino.   

Abstract

Plasma exchange has been reported to be a successful therapeutic procedure for the treatment of severely compromised myasthenic patients, but the optimal regimen in terms of costs or clinical benefit has not so far been determined. We have investigated the efficacy of a short plasmapheresis protocol of two exchanges 1 day apart in a series of 70 patients with severe forms of myasthenia gravis. Patients were evaluated before and 7 days after the first exchange. A positive outcome was observed in 70% of the plasma exchange cycles performed. Disease severity did not seem to be a negative prognostic factor for the efficacy of this short protocol, which was well tolerated by patients. In only 1 case were major side-effects observed. In spite of its short duration, the exchange treatment plus concomitant immunosuppressive drug therapy was not followed by early clinical deterioration.

Entities:  

Mesh:

Year:  1991        PMID: 1856735     DOI: 10.1007/bf00315690

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  27 in total

1.  Combined plasma exchange and immunosuppression in myasthenia gravis.

Authors:  J Newsom-Davis; A Vincent
Journal:  Lancet       Date:  1979-09-29       Impact factor: 79.321

2.  The utility of therapeutic plasmapheresis for neurological disorders. NIH Consensus Development.

Authors: 
Journal:  JAMA       Date:  1986-09-12       Impact factor: 56.272

3.  Time course of improved neuromuscular function following plasma exchange alone and plasma exchange with prednisone/azathioprine in myasthenia gravis.

Authors:  H S Milner-Brown; R G Miller
Journal:  J Neurol Sci       Date:  1982-12       Impact factor: 3.181

4.  Myasthenia gravis: prolonged treatment with steroids.

Authors:  A Sghirlanzoni; D Peluchetti; R Mantegazza; F Fiacchino; F Cornelio
Journal:  Neurology       Date:  1984-02       Impact factor: 9.910

5.  Plasma exchange alone as therapy for myasthenia gravis.

Authors:  J Keesey; D Buffkin; D Kebo; W Ho; C Herrmann
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

6.  Effect of plasmapheresis in myasthenia gravis 1978-1980.

Authors:  M R Olarte; R S Schoenfeldt; A S Penn; R E Lovelace; L P Rowland
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

7.  Plasmapheresis in refractory generalized myasthenia gravis.

Authors:  P Kornfeld; E P Ambinder; T Mittag; A N Bender; A E Papatestas; J Goldberg; G Genkins
Journal:  Arch Neurol       Date:  1981-08

Review 8.  Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients.

Authors:  K E Osserman; G Genkins
Journal:  Mt Sinai J Med       Date:  1971 Nov-Dec

9.  New antigen for antibody detection in myasthenia gravis.

Authors:  C Gotti; R Mantegazza; F Clementi
Journal:  Neurology       Date:  1984-03       Impact factor: 9.910

10.  Anti-acetylcholine receptor antibody titres in the sera of myasthenia patients treated with plasma exchange combined with immunosuppressive therapy.

Authors:  B Carter; R Harrison; G G Lunt; P O Behan; J A Simpson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-05       Impact factor: 10.154

View more
  10 in total

Review 1.  [Plasma exchange as a therapeutic option in neurological disorders].

Authors:  H C Lehmann; H P Hartung; G R Hetzel; B C Kieseier
Journal:  Nervenarzt       Date:  2007-02       Impact factor: 1.214

Review 2.  Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management.

Authors:  Fiammetta Vanoli; Renato Mantegazza
Journal:  Neurotherapeutics       Date:  2022-02-14       Impact factor: 6.088

Review 3.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

4.  Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravis: a randomised trial.

Authors:  Isha Trikha; Sumit Singh; Vinay Goyal; Garima Shukla; Rama Bhasin; Madhuri Behari
Journal:  J Neurol       Date:  2007-08-11       Impact factor: 4.849

5.  Autoimmune Myasthenia Gravis: Recommendations for Treatment and Immunologic Modulation.

Authors:  Vern C Juel; Janice M Massey
Journal:  Curr Treat Options Neurol       Date:  2005-01       Impact factor: 3.972

6.  Current and emerging therapies for the treatment of myasthenia gravis.

Authors:  Renato Mantegazza; Silvia Bonanno; Giorgia Camera; Carlo Antozzi
Journal:  Neuropsychiatr Dis Treat       Date:  2011-03-22       Impact factor: 2.570

Review 7.  Myasthenia gravis.

Authors:  Vern C Juel; Janice M Massey
Journal:  Orphanet J Rare Dis       Date:  2007-11-06       Impact factor: 4.123

Review 8.  Animal models of myasthenia gravis: utility and limitations.

Authors:  Renato Mantegazza; Chiara Cordiglieri; Alessandra Consonni; Fulvio Baggi
Journal:  Int J Gen Med       Date:  2016-03-04

9.  Predictors of extubation outcomes following myasthenic crisis.

Authors:  Zhenguo Liu; Shiyuan Yao; Qian Zhou; Zhensheng Deng; Jianyong Zou; Huiyu Feng; Hua Zhu; Chao Cheng
Journal:  J Int Med Res       Date:  2016-11-18       Impact factor: 1.671

Review 10.  Plasma exchange for myasthenia gravis.

Authors:  P Gajdos; S Chevret; K Toyka
Journal:  Cochrane Database Syst Rev       Date:  2002
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.